Iron chelation in the transfusion-dependent anaemias management is essential to prevent end-organ damage and to improve survival. Deferasirox is a once-daily orally active tridentate selective iron chelator which pharmacokinetic disposition could influence treatment efficacy and toxicity. Therapeutic drug monitoring is an important tool for optimizing drug utilization and doses.

Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients

ALLEGRA, SARAH
First
;
CUSATO, JESSICA;DE FRANCIA, SILVIA;PIRRO, Elisa;MASSANO, DAVIDE;PIGA, Antonio Giulio
Co-last
;
D'AVOLIO, ANTONIO
Co-last
2017

Abstract

Iron chelation in the transfusion-dependent anaemias management is essential to prevent end-organ damage and to improve survival. Deferasirox is a once-daily orally active tridentate selective iron chelator which pharmacokinetic disposition could influence treatment efficacy and toxicity. Therapeutic drug monitoring is an important tool for optimizing drug utilization and doses.
69
5
525
528
AUC; iron chelator; iron overload; transfusion; β-thalassaemia
Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio
File in questo prodotto:
File Dimensione Formato  
Allegra_et_al-2017-Journal_of_Pharmacy_and_Pharmacology.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 240.67 kB
Formato Adobe PDF
240.67 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1627890
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact